Australia markets close in 3 hours 32 minutes

Verrica Pharmaceuticals Inc. (VRCA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
7.26+0.50 (+7.40%)
At close: 04:00PM EDT
7.26 0.00 (0.00%)
After hours: 04:05PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 307.97M
Enterprise value 283.93M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)64.24
Price/book (mrq)15.58
Enterprise value/revenue 55.41
Enterprise value/EBITDA -4.57

Trading information

Stock price history

Beta (5Y monthly) 1.91
52-week change 32.11%
S&P500 52-week change 322.38%
52-week high 37.76
52-week low 32.86
50-day moving average 35.96
200-day moving average 35.03

Share statistics

Avg vol (3-month) 3148.44k
Avg vol (10-day) 3203.09k
Shares outstanding 542.42M
Implied shares outstanding 642.42M
Float 815.05M
% held by insiders 139.07%
% held by institutions 142.41%
Shares short (15 Apr 2024) 43.84M
Short ratio (15 Apr 2024) 422.54
Short % of float (15 Apr 2024) 420.46%
Short % of shares outstanding (15 Apr 2024) 49.04%
Shares short (prior month 15 Mar 2024) 44.4M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,036.17%

Management effectiveness

Return on assets (ttm)-62.56%
Return on equity (ttm)-224.08%

Income statement

Revenue (ttm)5.12M
Revenue per share (ttm)0.11
Quarterly revenue growth (yoy)2,823.50%
Gross profit (ttm)N/A
EBITDA -62.67M
Net income avi to common (ttm)-67M
Diluted EPS (ttm)-1.48
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)69.55M
Total cash per share (mrq)1.64
Total debt (mrq)45.51M
Total debt/equity (mrq)230.28%
Current ratio (mrq)4.55
Book value per share (mrq)0.47

Cash flow statement

Operating cash flow (ttm)-38.58M
Levered free cash flow (ttm)-17.12M